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A B S T R A C T
Introduction: The complement system, an essential part of the innate immune system, is involved in various
autoimmune diseases. Activation of the complement system by autoantibodies results in immune activation and
tissue damage. At the moment little is known about the role of the complement system in autoimmune liver
disease, including primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune
hepatitis (AIH). Since inhibition of the complement system is currently being tested in several autoimmune
diseases as a therapeutic option, its role in autoimmune liver disease requires further clarification.
Methods: A review of the literature was performed on studies investigating complement activation in PBC, PSC
and AIH. Since data on AIH were lacking immunohistochemical staining for IgG, C1q, C3d, C4d and C5b9 was
performed on liver tissue of nine AIH patients, two healthy controls and one positive control (acute liver failure
caused by paracetamol intoxication).
Results: Immunohistochemical analysis in AIH revealed increased production of C3 and C4 by hepatocytes.
Despite a strong staining for IgG in the immune infiltrate in AIH, C3d, C4d and C5b9 deposition was only present
in one AIH patient and the deposition was restricted to the interface between portal tracts and liver parenchyma.
No deposition was found in all other AIH patients or healthy controls.
Literature review showed raised plasma C3 and C4 levels in AIH, PBC and PSC patients compared to healthy
controls. For PBC and PSC no complement depositions at the bile ducts were reported.
Conclusion and discussion: Although complement is involved in various autoimmune diseases, the role of com-
plement in autoimmune liver disease seems limited. Therefore it is unlikely that complement inhibition will
become a novel treatment option for these diseases.
1. Introduction
The complement system is an essential part of the innate immune
system and well known for its role in the immune response against
infections [1]. It is also involved in instructing the adaptive immune
response and several physiological processes such as clearance of im-
mune complexes and apoptotic cells, neovascularization, nerve pruning
and tissue regeneration. Unfortunately the powerful immune effector
mechanisms of complement can also be directed against the host tissue
in the setting of autoimmunity or transplantation and contribute to
tissue damage. Examples of autoimmune diseases where complement is
involved in tissue damage are rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE) and ANCA associated vasculitis (AAV) [2–5]. With
the successful introduction of C5 inhibitor Eculizumab for atypical
hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria,
it became clear that the complement system can be targeted in vivo
[6,7]. This spurred the development of a wide array of complement
inhibitors blocking several steps in the complement cascade [8].
Complement inhibition was thought to be particularly effective in au-
toimmune diseases. The use of complement blocking therapeutics will
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also lead to a better understanding of the relative contribution of
complement activation in the various disease processes. However, even
if complement is involved in a disease process complement inhibitory
treatment will always be initiated after the onset of clinically overt
symptoms, which may render it less successful than earlier treatment. It
is clear that complement plays an important, yet complex, role in au-
toimmune diseases.
While complement is important in several autoimmune diseases,
little is known about the role of complement in autoimmune liver dis-
ease.
1.1. Complement system and the liver
The complement system is a highly preserved part of the innate
immune system. The complement cascade can be activated through
three pathways: the classical pathway, the alternative pathway and the
lectin pathway. C1q is the first protein of the classical pathway and can
recognise immunoglobulins bound to an antigen [9]. After binding of
C1q, C3 and C4 become activated finally resulting in formation of the
membrane attack complex (MAC) consisting of C5b9. The complement
system can also be activated by the lectin pathway after binding of
microbial surface molecules to mannose binding lectin (MBL). In the
alternative pathway a C3 tick-over leads to conversion of C3 and C5
without conversion of C4. The MAC, by damage to the cell membrane,
can cause lysis of cells and tissue damage. Moreover, opsonization by
binding of C3b facilitates phagocytosis by macrophages. Complement
activation fragments C5a and C3a are anaphylatoxins and can recruit
additional immune cells to the location of complement activation. C5
can also stimulate hepatocyte proliferation after liver damage and
promote liver regeneration [10]. The role of complement in liver re-
generation and transplantation has been reviewed recently [10].
Whether complement is involved in a disease process or not is often
indirectly deduced based on decreased plasma levels of complement
proteins as a consequence of consumption, the presence of activated
complement fragments in the circulation or the presence of activated
complement fragments in the target tissues on histology [11]. Plasma
levels of complement proteins are determined by production and con-
sumption by activation. Production of most complement factors occurs
mainly in the liver. In the liver C3 and C4 are produced by hepatocytes.
Kupffer cells, the liver resident macrophages, produce C1q [12]. Pro-
duction of complement proteins can be decreased in liver cirrhosis, as is
the case with other proteins like albumin [13]. Systemic inflammation
can increase complement protein production by the liver and can
thereby cause increased plasma complement levels [14]. Excessive ac-
tivation can cause decreased plasma levels due to consumption, as seen
in SLE [2].
Even if signs of complement activation are present it still needs to be
determined whether the complement activation is contributing to in-
flammation and tissue damage or if the complement activation is ben-
eficial by orchestration waste disposal and tissue regeneration.
1.2. Autoimmune diseases of the liver
The liver is an organ with a unique immunotolerance compared to
other organs. It is continuously exposed to bacterial products from the
intestines, and without immunotolerance the liver would be constantly
inflamed [15]. Another manifestation of the immunotolerant nature of
the liver is in the context of transplantation: rejection is less prevalent
in liver transplantation than in kidney or heart transplantation patients.
Some reports suggest that up to 25% of the liver transplant patients can
be weaned from immunosuppression [16]. A transplanted liver can also
lead to partial operational tolerance for other transplanted organs, like
a simultaneously transplanted kidney [17].
Despite the liver being a tolerogenic organ, autoimmune diseases of
the liver do exist. The three main distinctive autoimmune diseases of
the liver are autoimmune hepatitis (AIH), primary biliary cholangitis
(PBC) and primary sclerosing cholangitis (PSC).
1.3. Autoimmune hepatitis
Autoimmune hepatitis (AIH) is characterized by a lymphoplasma-
cytic infiltrate, interface hepatitis, raised total IgG and autoantibodies
[18]. It has a predominance in females and can present at all ages
[19,20]. Type 1 AIH is the most prevalent and is characterized by
smooth muscle antibodies (SMA) and antinuclear antibodies (ANA).
Type 2 AIH is characterized by the highly specific liver-kidney-micro-
some-1 (LKM-1) antibodies and presents more often in childhood [21].
Treatment is the same for both types of AIH and consists of prednisone
and azathioprine. As second-line therapy mycophenolate mofetil is
frequently used [22]. Treatment leads to a decrease in liver enzymes
and IgG and normalization in about 80% of the patients [23], but this
can take several years [19]. For the patients not rapidly reaching re-
mission and patients with significant side-effects of treatment with
prednisone and azathioprine, there is a clinical need for new therapies
and new therapeutic targets.
Due to the presence of autoantibodies and high IgG levels formation
of antibody-antigen complexes in the liver can be expected in AIH.
These antibody-antigen complexes might then activate complement
through the classical pathway leading to the formation of MAC, causing
damage to the hepatocytes. At the moment no studies regarding the role
of complement in adult AIH patients have been published.
The aim of this study was to assess the complement cascade in AIH
patients using immunohistochemistry and perform a literature review
on the role of complement in autoimmune liver disease.
2. Methods
2.1. Immunohistochemical analysis in AIH
AIH patients with at least probable type I AIH according to the
simplified criteria with available liver biopsy at diagnosis were eligible
for inclusion [24]. Two tissue samples of healthy liver parenchyma
obtained of liver resections for colorectal metastasis were used as
normal control tissue. One tissue sample of acute liver failure after
paracetamol intoxication was used as positive control, as due to the
excessive liver damage and necrosis the complement system was ex-
pected to be activated. All AIH patients gave informed consent for the
use of their data and biopsy material. As the tissue of the positive and
healthy controls were used anonymously no informed consent was
needed.
Formalin fixed, paraffin embedded sections of liver parenchyma
were stained using the following antibodies IgG, C1q, C3d, C4d and
C5b9. Staining was performed according to laboratory standard pro-
cedures. Sections were deparaffined with xylene and subsequently re-
hydrated with graded alcohol solutions. 0.3% hydroperoxide (H2O2)
was used to block endogenous peroxidase activity. After antigen re-
trieval the tissue was incubated with the primary antibody overnight at
room temperature. Rabbit and mouse Envision were used as secondary
antibody. Detailed information regarding used antibodies and staining
procedure used are given in Appendix A. Visual assessment was used as
quantification method and all stained tissue was scored for degree and
location of the staining.
2.2. Literature review autoimmune liver disease
Pubmed and Embase were searched using the terms: autoimmune
hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis, pri-
mary biliary cholangitis, complement, complement system, C4d, C5b9
and combinations of these terms. Titles and abstracts of articles were
read. If articles discussed complement activation in autoimmune liver
disease the full article was read. Results were summarized in a review.
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3. Results
3.1. Immunohistochemical analysis in AIH
To provide insight into the possible role of complement activation in
type I AIH a immunohistochemical analysis of complement proteins
was performed. Nine treatment naïve type 1 AIH liver biopsies were
included in this study. Median age at diagnosis was 54 years (range:
16–68 years). Further baseline characteristics can be found in Table 1.
IgG staining was present in the infiltrate of all patients with increased
intensity in plasma cells. Liver sinusoids were positive for IgG in AIH
patients and in healthy controls (Fig. 1).
C1q staining was present in Kupffer cells in the sinusoids, in AIH
patients and healthy controls. Intracellular staining of C3 and C4 was
detected using antibodies specific to the C3d and C4d fragments of the
C3 and C4 proteins. Staining was more intense in patients with AIH
compared to healthy controls. In the patient with acute liver failure due
to paracetamol intoxication intense C3d and C4d deposition with the
same localization as the C5b9 deposition was seen. In patients with AIH
C3d and C4d staining did not correspond to C5b9 staining (Fig. 1).
C5b9 staining, a marker of complement activation, was only present in
1 of the 9 AIH patients and in none of the healthy controls (Table 2). In
this patient the C5b9 staining was present in the extracellular matrix on
the interface between infiltrate and hepatocytes (Fig. 2).
Table 1
Clinical characteristics of AIH patients.
Age Gender IgG level in g/L ALT Initial treatment Response
1 16 Female 34.1 926 Prednison + AZT Remission < 12 months
2 24 Female 21.9 668 Prednison + AZT Remission < 12 months
3 53 Female 19.1 259 Prednison +6TG Remission < 6 months
4 54 Male 20.5 94 Budesonide Remission < 6 months
5 54 Male 39 391 Prednison + AZT Remission < 6 months
6 59 Male 14.3 418 Prednison Incomplete response
7 59 Female 18.7 48 Budesonide + AZT Remission < 6 months
8 64 Female 20.1 189 Prednison + AZT Remission < 6 months
9 68 Male 29.3 1314 Prednison Remission < 12 months
Used abbreviations: IgG immunoglobulin G; ALT alanine aminotransferase; AZT azathioprine; 6TG 6-thioguanine.
Fig. 1. Results of complement cascade in AIH, healthy control and acute liver failure. Staining for IgG, C1q, C3d, C4d and C5b9 are shown.
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3.2. Literature review AIH
Current literature regarding the role of complement in AIH is very
limited. C3 levels were elevated in an AIH mouse model and in plasma
of AIH patients compared to healthy humans and mice controls re-
spectively [25]. One report mentioned that on immunohistochemistry
C4d deposition was present in 83% of the patients with paediatric AIH.
Depositions were reported to be present in the immune infiltrate and
extended to the periportal sinusoids in some patients. The same fre-
quency of C4d deposition was found in patients with hepatitis B [26].
Little to no C5b9 deposition was seen in another study in paediatric AIH
[27]. No reports discussing the role of complement in adult AIH pa-
tients were found in the literature review.
3.3. Literature review on PBC
Primary biliary cholangitis (PBC) is an autoimmune disease of the
liver which targets the intralobular bile ducts. The incidence is higher
in women (1.9 per 100.000) than in man (0.3 per 100.000) [28]. The
disease is characterized by anti-mitochondrial antibodies (AMA) (pre-
sent in> 90% of the patients) and high serum IgM [29]. Pyruvate de-
hydrogenase complex (PDC)-E2 subunit, a protein normally expressed
in the mitochondria but which can be present on cholangiocytes, is the
main target of the antimitochondrial antibodies in PBC [30]. Con-
tinuous bile duct inflammation leads to ductopenia (bile duct loss),
cholestasis and development of fibrosis and liver cirrhosis.
Treatment with ursodeoxycholic acid (UDCA) can decrease choles-
tasis, prevent progression to cirrhosis and improve survival [31,32].
Obeticholic acid and bezafibrate can be used as second line therapy in
patients with an inadequate response to UDCA [33,34].
The role of complement in PBC has been described in a limited
number of studies. The presence of AMA with a target on the cho-
langiocytes could result in formation of autoantibody-antigen com-
plexes, triggering the classical pathway of the complement system.
While in the prototype autoimmune disease SLE often decreased levels
of circulating C3 and C4 are detected, in plasma of patients with PBC
increased C3 and C4 levels compared to healthy controls were found in
all studies [2,35–37]. These increased levels were also present in non-
autoimmune forms of hepatitis (alcoholic and viral). A likely explana-
tion is increased production by the liver due to the inflammation, the
acute phase reaction. In cirrhotic PBC patients C3 and C4 levels de-
creased, probably reflecting the reduced protein synthetic capacity of
the cirrhotic liver [36].Levels of activated complement fragments in-
cluding C3a, C4a and C5b9, were not elevated in the plasma of PBC
patients compared to healthy women [36].
On immunohistochemistry no C3d and C5b9 deposition was seen at
the bile ducts of PBC patients [38]. No evidence of complement acti-
vation could be found in the plasma complement protein levels, acti-
vated fragments in the plasma or on immunohistochemistry. In con-
clusion although the disease is characterized by anti-mitochondrial
antibodies, the classical complement pathway does not seem to be ac-
tivated and does not seem to importantly contribute to the damage to
cholangiocytes in PBC.
3.4. Literature review on PSC
Primary sclerosing cholangitis (PSC) is a progressive disease with
development of strictures in large and small bile ducts. The incidence is
estimated to be 0.5 per 100.000. The disease affects males twice as
often as females. Co-existent inflammatory bowel disease is present in
70% of the patients [39]. Bile duct strictures cause chronic cholestasis
and recurrent cholangitis, which both can lead to fibrosis and liver
cirrhosis. Patients have an almost 400 fold increased risk for cho-
langiocarcinoma compared to the general population [39]. No specific
autoantibodies are present in PSC, although antineutrophil cytoplasmic
antibodies (ANCA), ANA and SMA can be positive.
At the moment liver transplantation is the only curative treatment
option, although UDCA treatment can improve alkaline phosphatase
levels in some of the patients [40–42]. Several trials with different
medication have been and are being conducted, but at the moment
none has been proven effective yet in reducing disease progression and
improvement of long-term outcome [43]. There is a great need for new
therapeutic options. If complement inhibition, by example eculizumab,
could reduce bile duct damage, it might be a therapeutic option pre-
venting progression in PSC.
Only a limited number of studies have been performed on the role of
complement in PSC. Plasma C3 levels were elevated in PSC patients
compared to healthy controls [44]. Since the same elevation of C3 le-
vels was present in choledocholithiasis patients compared to healthy
controls, inflammation could be an explanation for the raised C3 levels
Table 2
Results of immunohistochemical stainings.
Patient 1 2 3 4 5 6 7 8 9 HC HC ALF
IgG Infiltrate + + + + + + + + + NA NA NA
Sinusoids + + + + + − + + + + + −
C1q Kupffer cells + + + + + + + + + + + +−
Deposition − − + − − − − − − − − ++
C3d Hepatocytes + + + +− + + + + + − − −
Deposition − − + − − − − − − − − ++
C4d Hepatocytes + + + +− + + + +− + − − −
Deposition − − + − − − − − − − − ++
C5b9 Deposition − NAa + − − − +−b − − − − ++
Used abbreviations: HC healthy control; ALF acute liver failure; NA not applicable.
a For this staining not enough tissue was available for reliable evaluation.
b Traces of C5b9 were present in the immune infiltrate.
Fig. 2. C5b9 deposition in an AIH patient.
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in PSC. No difference was found in C4 levels between PSC and healthy
controls [44].
Levels of activated complement fragments, C3d and C4d, were
elevated in PSC patients compared to healthy controls and patients with
extrahepatic obstructive cholestasis [44]. However, in another study,
on immunohistochemistry no C3d and C5b9 depositions could be found
in the bile ducts of PSC patients [38].
In conclusion, the available data in PSC patients indicates that if
any, the role of the complement system seems limited in this disease.
4. Conclusion and discussion
To our knowledge the present study is the first study to assess the
complete complement cascade in adult type I AIH patients and healthy
controls. Due to the presence of autoantibodies, plasma cells and IgG,
activation of the classical pathway of the complement system seemed
probable. C1q staining was present, but restricted to Kupffer cells. C3d
and C4d staining was more intense in hepatocytes of AIH patients
compared to healthy controls. This could be explained by the increased
production of complement in liver due to inflammation, as previously
reported [25,35–37,44]. Indeed, C3d and C4d staining was not related
to C5b9 staining and the staining was cytoplasmatic, supporting the
hypothesis that the positivity is more likely the result of increased
synthesis than of deposition. The anti-C4d antibody used in our studies
binds to C4d, which is a part of the C4 molecule and not an neoepitope.
The antibody detecting C5b9 binds to a neoepitope that is not produced
by the liver and is a true marker of complement activation. However, in
the current AIH patients C5b9 deposition was only present in one of the
nine AIH patients, mostly at the interface. Autoantibodies in most AIH
patients did not result in the formation of the membrane attack com-
plex, so that complement does not seem to play a role as the cause of the
liver damage in AIH.
IgG staining was positive in the immune infiltrates and in the si-
nusoids. Staining of sinusoids in AIH and healthy control, could be
explained by the Fc-gamma IIb receptor physiologically present on si-
nusoids in order to bind and take up small IgG immune complexes to
promote immunotolerance in the liver [43,44].
Complement has an important role in several autoimmune diseases
including rheumatoid arthritis, SLE and ANCA associated vasculitis
[11]. Although the presence of plasma cells, autoantibodies and IgG are
hallmarks of AIH, the data presented here indicate that activation of the
classical pathway of the complement system does not seem to be of
importance in the pathophysiology of AIH. Despite the fact that in
ANCA associated vasculitis, anti-MPO or anti-PR3 antibodies are pre-
sent, the complement activation is reported to occur mainly through the
alternative pathway [5]. If complement is activated through the alter-
native pathway no IgG, C1q and C4d depositions are expected but C3d
and C5b9 depositions in target tissue are expected. In AIH we found
increased production of C3 but no depositions of C3d and C5b9, in-
dicating also a limited role for the alternative pathway in the patho-
physiology of AIH. Hepatic injury does not seem to be caused by au-
toantibodies and complement activation. Alternatively autoreactive B-
cells producing cytokines or autoreactive T-cells may be the cause of the
hepatic injury. Further understanding of the pathophysiological me-
chanism of liver damage in AIH is important for development of new
therapies.
Current therapies for AIH, including prednisolone, azathioprine and
mycophenolate mofetil, are targeting T-cells reducing T-cell activation
and proliferation [45]. While only around 1% of AIH patients are
treatment-refractory, in around 20% of the patients complete remission
is not reached within a few years due to partial ineffectiveness or in-
tolerance to the treatment. This, in combination with the long term
side-effects of prednisone including osteoporosis and diabetes mellitus,
highlights the need for new treatment strategies in AIH.
The field of drugs inhibiting the complement system is rapidly ex-
panding and includes very prominently rheumatic and autoimmune
disease [8,11,46]. C5 inhibitor Eculizumab is an effective therapy for
some autoimmune diseases and has been approved for atypical hemo-
lytic uremic syndrome and paroxysmal nocturnal hemoglobinuria
[6,7]. Studies are being conducted in myasthenia gravis, membrano-
proliferative glomerular nephritis and neuromyelitis optica to broaden
the indications for Eculizumab [8]. For ANCA associated vasculitis a
C5a receptor antagonist (CCX168) is being tested in clinical trials [5]. A
C3 activation inhibitor is tested for membranous nephropathy [8].
Since in AIH we did not observe evidence to suggest that the auto-
antibodies activated the complement system in the liver, eculizumab is
unlikely to become a new therapy for AIH. Moreover, inhibition of C5
could even be detrimental as it might limit liver regeneration and in-
crease disease severity.
Intravenous immunoglobulins (IVIG) or plasmapheresis can reduce
the concentration of auto-antibodies and are effective treatment options
in several autoimmune diseases including Guillain-Barré syndrome,
immune thrombocytopenia and myasthenia gravis [47–49]. Although
autoantibodies are frequently present in autoimmune liver disease, IVIG
and plasmapheresis are unlikely to be effective treatment options for
these diseases, as the activation of the classical complement pathway is
very limited.
B-cell targeted therapies like rituximab could be effective if liver
damage is partially caused by cytokines produced by autoreactive B-
cells instead of by auto-antibodies. Small case series on the sometimes
successful use of rituximab in AIH have been published [50].
Literature review into the role of complement in PBC and PSC
showed increased levels of complements proteins in plasma, with in-
flammation as the most likely explanation. No activation of the classical
or alternative complement pathway was present on liver histology.
Based on these results the role of the complement system in the biliary
damage seen in PSC and PBC seems limited as well, and targeting the
complement system is not likely to be an new therapeutic option in
these diseases.
In some other liver diseases the complement system does seem to
fulfill an important role. For instance, in antibody mediated rejection
after liver transplantation C4d deposition on liver biopsy is one of the
diagnostic criteria [51]. Polymorphisms in the lectin-pathway of com-
plement activation can increase the risk for infections after liver
transplantation [52,53]. In non-alcoholic fatty liver disease (NAFLD)
and non-alcoholic steatohepatitis (NASH) C3d and C5b9 deposition
around steatotic hepatocytes were present in up to 50% of the patients
[54]. However, even if complement is activated, the causative role of
the complement system in the pathophysiology of these diseases still
needs to be further investigated since damaged host tissue can also
activate complement and complement is important for waste disposal
and liver regeneration [10].
In conclusion, although the complement system is involved in var-
ious autoimmune diseases and some liver diseases, the role of com-
plement in AIH, PBC and PSC seems limited. Based on this limited role,
therapies aiming at complement inhibition, like eculizumab, IVIG and
plasmapheresis are unlikely to become new therapeutic options in these
diseases.
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